This clinical trial is focused on studying the effects of stopping a medication called omalizumab, which is used to treat a condition known as severe allergic asthma. Severe allergic asthma is a type of asthma that is difficult to control and is triggered by allergies. The medication being studied, omalizumab, is given as an injection and helps to manage asthma symptoms by targeting specific proteins in the body that cause allergic reactions.
The purpose of the study is to see if patients with well-controlled severe allergic asthma can safely stop taking omalizumab after using it for at least three years. Participants in the study will be divided into two groups: one group will continue receiving omalizumab, while the other group will stop the treatment. The study will monitor the number of asthma flare-ups, which are periods when asthma symptoms suddenly get worse, over the course of a year. These flare-ups often require additional medication to manage.
Throughout the study, researchers will also assess changes in asthma control and quality of life, as well as any changes in lung function and the use of other asthma medications. The study aims to determine if stopping omalizumab is as effective as continuing it in maintaining asthma control. Participants will be followed for a total of 12 months to gather this information.
France 
